Javascript must be enabled to use this website


(N sal yoo ta mide)
Xtandi MDV3100
CategoryDHT reducer

Parameter Effect Result on hair growth
5a-reductases GOOD


Description Enzalutamide (MDV3100 and RD162) are unique compared to currently prescribed AR antagonists because they disrupt activity in three complementary ways:

First, they block binding of DHT to AR by occupying the ligand binding site where DHT usually binds. This first line of defense keeps the receptor from being activated by DHT that is normally produced in the body.

Second, the compounds impede movement of AR into the cell nucleus, where the receptor normally binds to DNA and regulates the expression of genes. By keeping AR in the cytoplasm, MDV3100 and RD162 physically isolate the receptor from its site of action.

Finally, they change the shape of AR and reduce its ability to interact with DNA. When the receptor binds to DNA sequences in the genome, it acts as a molecular "on/off switch" for genes that alter cellular behavior.

This third activity is critical for preventing any receptors that are already present in the nucleus from binding to DNA and regulating the expression of genes that are presumably responsible for hair loss.

MDV3100 has a higher affinity for AR and inhibits the receptor more effectively than other currently prescribed anti-androgens like bicalutamide. Initial observations in a Phase I/II clinical trial for advanced prostate cancer have shown promising results and Phase II/III trials are in progress.

Since the Nobel Prize-winning discovery by Huggins and Hodges in 1941 [1] that reducing circulating testosterone levels by orchidectomy or exogenous estrogens has a beneficial effect on patients with prostate cancer, androgen-deprivation therapy (ADT) has become the mainstay of treatment for advanced disease. However, most patients will eventually progress on this treatment and develop what has previously been termed ‘hormone-refractory’ prostate cancer. This is a misnomer as several studies have shown that newer, more sophisticated antiandrogens and hormone biosynthesis inhibitors can continue to have significant activity in a proportion of patients, even at very advanced stages.

Antiandrogens are oral compounds that compete with endogenous ligands for the androgen receptor (AR), and thereby block the biological effects of testosterone and dihydrotestosterone. When bound they induce a conformational change that impedes transcription. These drugs can be broadly split into two categories: steroidal and nonsteroidal. Steroidal antiandrogens, such as cyproterone acetate, were the first to emerge. These are broad-acting drugs, however, and can be associated with a wide range of side effects. This led to the development in the 1970s of nonsteroidal agents, such as flutamide, nilutamide and bicalutamide, which are better tolerated.

Bicalutamide has been extensively investigated in the Early Prostate Cancer program. This multicenter, prospective trial randomized 8113 men with nonmetastatic disease to bicalutamide 150 mg or placebo in addition to standard care. Standard care could be with surgery (radical prostatectomy), radical radiotherapy or watchful waiting where appropriate. The fourth and final analysis, with a minimum follow-up of 10 years, showed significant advantages for men with locally advanced disease in terms of progression-free survival [2]. There was also a highly significant improvement in overall survival in favor of bicalutamide when used as an adjuvant to radiotherapy for men with locally advanced prostate cancer.

Bicalutamide monotherapy has been shown to be inferior to castration-based treatment with luteinizing hormone-releasing hormone agonists when used to treat metastatic disease [3], but it is commonly used in combination with luteinizing hormone-releasing hormone agonists with good effect. This effect tends to be temporary and patients will ultimately progress on combined androgen blockade. A withdrawal effect is occasionally seen with the cessation of the antiandrogen therapy, demonstrating that they can develop partial agonist activity [4].

Castrate-refractory prostate cancer (CRPC) is defined as progressive disease in the context of castrate levels of androgens. A proportion of these men will, however, still respond to further lines of hormonal therapy, suggesting that AR signaling continues to be important. This has led to research investigating AR signaling and the mechanisms that occur in ‘castrate-resistant’ disease in an attempt to develop targeted therapies to interrupt this process. There are several mechanisms by which CRPC manages to overcome androgen-deprivation therapy in order to maintain tumor growth. These include AR overexpression [5], AR mutation, which can allow activation by other ligands, for example, progesterone and hydrocortisone [6], ligand-independent activation by growth factor signaling pathways, and upregulation of the enzymes involved in androgen biosynthesis, thus resulting in higher intratumoral androgen concentrations [7].

Extensive research has been carried out in recent years to develop more specific and efficacious methods of androgen blockade. One of the most significant recent advances has come from Sawyer and colleagues [8]. They screened derivatives of the nonsteroidal AR antagonist RU59063 for pure antagonistic activity. This process produced two drugs, MDV3100 and RD162. These oral compounds both demonstrated five to eight times higher affinity for the AR than bicalutamide without its partial agonist activity. Importantly, MDV3100 in particular does not activate wild-type AR receptors or certain mutated ARs.

The mechanism of MDV3100 is threefold. First, it has a much stronger affinity for the AR, second it inhibits AR nuclear translocation, and third, it appears to induce a conformational change that impairs binding to DNA and cofactor recruitment. MDV3100 also has no known agonist activity when AR is overexpressed. Preclinical trials have demonstrated the anti-tumor activity of MDV3100 in both in vitro and in vivo models. In mice with LNCaP/AR xenograft tumors, MDV3100 induced tumor regression where bicalutamide only slowed growth [8].

MDV3100 has been investigated in Phase I and II studies in men with CRPC [9]. One hundred and forty patients with progressive castration-resistant prostate cancer were enrolled, the majority (78%) with metastatic disease and approximately half of whom had received prior chemotherapy. The results demonstrated promising activity with prostate-specific antigen (PSA) declines in serum PSA of 50% or more in over 50% of patients. In addition, two-thirds of patients achieved either a partial response or stable disease radiologically. Better outcomes were seen in the chemotherapy-naive group, with the median time to radiological progression being 47 weeks compared with 29 weeks.

MDV3100 was well tolerated, with the only reported grade 3 or above toxicity being fatigue in 11% of patients. This was only observed at doses of 240 mg or higher. Seizures were reported in three patients, all of whom were taking doses above 360 mg and were also concurrently being treated with other medications that may have contributed to a lower seizure threshold. The maximum tolerated dose was established as 240 mg; no additional anti-tumor effect was observed at greater doses [9]. Subsequent studies have used 160 mg as the dose of MDV3100 to be tested.

This promising activity led to the initiation of two large Phase III studies in metastatic CRPC. The AFFIRM study is a large, double-blind, randomized trial of 1199 men with advanced CRPC who had previously received docetaxel-based chemotherapy. Men were randomized in a 2:1 manner to MDV3100 or placebo. Patients treated with MDV3100 demonstrated a 4.8-month survival benefit (18.4 vs 13.6 months) compared with those receiving placebo (p < 0.0001), with a 37% reduction in risk of death. The study was unblinded at interim analysis on the basis of these results and those receiving placebo will be offered MDV3100 [101].

MDV3100 has been shown to be a safe, well-tolerated oral drug that has a significant survival advantage in postchemotherapy patients. This is a major step forward in our understanding of the continuing relevance of the AR and its downstream effects. The second Phase III study in CRPC is the PREVAIL study. This is a large, randomized, placebo-controlled trial in patients with progressive, metastatic castration-resistant prostate cancer who are chemotherapy naive. This study aims to recruit 1680 patients who will be randomized to MDV3011 or placebo on a 1:1 basis. The primary outcomes to be analyzed are overall and progression-free survival.

Ongoing and extensive research into the field of AR targeting has yielded important developments in the treatment of prostate cancer. In addition to MDV3100, abiraterone acetate, a novel androgen biosynthesis inhibitor, has also been shown to significantly increase the overall survival benefit in men with metastatic CRPC postchemotherapy [10]. The advent of these two new drugs represents a major step forwards in our understanding of the biology and management of this complex disease. The AR remains an increasingly relevant therapeutic target and an important area for current research.

Typical Results Unknown.
Typical Dosages N/A
Significant Side Effects N/A
Pharmacology Pharmacodynamics N/A

Clinical Studies

Clinical StudiesAbstract
The evolution of antiandrogens: MDV3100 comes of age.. Full Text PDF
Pathophysiology and therapy of castration-resistant prostate cancer. Advanced prostate cancer that progresses under androgen deprivation therapy has long been thought to be refractory to further hormonal treatment. The identification of the mechanism of cancer cells has revolutionized this understanding. Today it is known that castration-resistant prostate cancer (CRPC) still receives signals through the androgen receptor transduction pathways and furthermore is sensitive to hormone therapy. New substances, such as abiraterone, enzalutamide (MDV3100) and TAK 700 target these mechanisms of resistance of cancer cells, stop testosterone production and show not only better tolerance but also effective antitumor activity. Due to the heterogeneity of tumors with cells in varying states of differentiation, the treatment of CRPC with androgen deprivation therapy remains a cornerstone of disease management. To what extent the experimental findings and the recommendations in the guidelines are put into practice was the subject of a survey among urologists analyzing their treatment strategies with CRPC patients.
Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer.. Recent therapeutic advances for managing advanced prostate cancer include the successful targeting of the androgen-AR axis with several new drugs in castrate resistant prostate cancer including abiraterone acetate and enzalutamide (MDV3100). This translational progress from "bench to bed-side" has resulted in an enlarging repertoire of novel and traditional drug choices now available for use in advanced prostate cancer therapeutics, which has had a positive clinical impact in prolonging longevity and quality of life of advanced prostate cancer patients. In order to further the clinical utility of these drugs, development of predictive biomarkers guiding individual therapeutic choices remains an ongoing challenge. This paper will summarize the potential in developing predictive biomarkers based on the pathophysiology of the androgen-AR axis in tumor tissue from patients with advanced prostate cancer as well as inherited variation in the patient's genome. Specific examples of rational clinical trial designs incorporating potential predictive biomarkers from these pathways will illustrate several aspects of pharmacogenetic and pharmacogenomic predictive biomarker development in advanced prostate cancer therapeutics.
Androgen receptor directed therapies in castration-resistant metastatic prostate cancer.. OPINION STATEMENT: Recent results of phase III randomized studies confirm that targeting the androgen receptor (AR)-through inhibition of androgen synthesis or through AR targeting directly-can improve survival for patients with metastatic castration-resistant prostate cancer (mCRPC), a condition previously considered to be "refractory" to further hormonal manipulation. These data validate in the clinical setting much of the scientific work of the previous decade that has demonstrated the extent of and mechanisms behind retained AR signaling in advanced prostate cancer. The convergence of these observations effectively changes the perspective with which androgen deprivation is utilized in prostate cancer, and forms the basis for further expansion of systemic therapy in the disease. In this review, the rationale for and clinical results with these new therapies will be discussed as will the future directions required to fully leverage these therapeutic modalities to the maximum clinical benefit for patients.


The contents of this website comes from personal experiences and observations, meant only for educational purposes and not intended to replace medical advice, consultations, or treatment of any kind. Please see your professional health care provider to discuss topics on this site.

Copyright, 2006-2012. All rights reserved.